stockrow
Saturday 7 November 2026
Export AFMDQ’s income statement to Excel — free account
Affimed N.V.
AFMDQ Healthcare Biotechnology
Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.
0.00
0.00
NaN
Follow AFMDQ
Alert me
Affimed N.V. (AFMDQ) P/E ratio
Affimed N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 10.1× (July 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
Low 0.0×
High 10.1×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| KALA KALA BIO, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| AFMDQ Affimed N.V. | n/m |
| DCOY Decoy Therapeutics Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)